ESG News For Transgene Biotek Ltd

The Dion Foundation for Children with Rare Diseases will finance expansion in the US of Atamyo’s first-in-human trial of ATA-200.The Phase 1b, dose-escalation study to evaluate the safety and efficacy of ATA-200 in children has already received regulatory clearance in Europe.ATA-200 is a single-injection gene therapy aimed to treat limb-girdle muscular dystrophy Type 2C/R5 (LGMD2C/R5) caused by mutations in the g-sarcoglycan gene

The recent comments made by former President Donald Trump regarding a bill that would determine a person’s gender assignment only at birth have been met with widespread criticism and opposition from the transgender community and its allies. For decades, the transgender community has been fighting for recognition and acceptance. This newly proposed bill not only puts their basic human rights in jeopardy, but also is a cruel and misguided attempt to erase the experiences and identities of transgen